Skip to main content
ConductScienceScienceDex

Sean Adam Wasserman

NIH Rank #14009
Unclaimed recordClaim profile
  • Program Leader
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 15185839Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.

NIH Funding · FY2025

Linked Award Amount
$1.2M
Full award amounts, FY2025
Award Records
3
Records listing this PI
Award-Linked Rank
#14,009
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Sean Adam Wasserman. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2025 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2025 award records by amount

NIH award records listing Sean Adam Wasserman as a PI. Multi-PI records show the full award amount for context.

  • 3U01AI170426-04S2U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $406.5K
    award amount
  • 3U01AI170426-04S1U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $398.3K
    award amount
  • 5U01AI170426-04U01
    PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis
    Brigham and Women's Hospital
    $366.2K
    award amount

Award organization

Organizations that administered FY2025 awards listing Sean Adam Wasserman as a PI.

FY2025 award administered by Brigham and Women's Hospital (MA).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2024
    First NIH Award
    Brigham and Women's Hospital
  2. 2024
    $500K Cumulative Funding
  3. 2024
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding

Shared-award investigators

Other investigators listed on at least one of the same NIH award records as Sean Adam Wasserman.

Serena Patricia Koenig
Brigham and Women's Hospital
4
shared awards

Explore further

Find collaborators for Sean Adam Wasserman

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →